摘要
科学量化评估我国医药创新能力与潜力,分析发现医药创新过程中的问题并提出建议;创新过程评价指标体系构建,采集2008—2018年中国、美国、日本临床试验开展、药物研发数量、专利数量与论文发表数量等数据,采用描述性统计分析与动态TOPSIS法;我国在临床试验、药物研发、专利申请和论文发表数量层面上发展迅猛,动态TOPSIS法综合评价我国医药创新潜力初步赶超日本;我国医药产业处于快速发展期,创新发展要继续重视基础研究,加强科研项目管理,引导多渠道资金融通,深化审评审批制度改革,完善知识产权保护制度,加快打造科研创新平台等。
Objective:To scientifically and quantitatively evaluate China's pharmaceutical innovation capabilities,analyze problems in pharmaceutical innovation and make recommendations;Methods:Constructed innovation process evaluation index system,Collected the data of clinical trials,medicine development,patents,and publications in China,the United States and Japan during 2008—2018,used descriptive statistical analysis and dynamic TOPSIS;Results:China developed rapidly in the number of clinical trials,medicine development,patents and publications.The comprehensive evaluation result of the dynamic TOPSIS method is that China has initially surpassed Japan;Conclusions:China's pharmaceutical industry is in a period of rapid development.Continue to focus on basic research,strengthen scientific research project management,improve the intellectual property protection system,deepen the reform of the review and approval system and accelerate the creation of scientific research innovation platforms.
作者
张铭洺
茅宁莹
Zhang Mingming;Mao Ningying(International Pharmaceutical Business School,China Pharmaceutical University,Jiangsu Nanjing China,211198)
出处
《科技管理研究》
CSSCI
北大核心
2020年第21期23-30,共8页
Science and Technology Management Research
基金
国家社会科学基金项目“我国创新药物政策环境研究”(15ZDB167)
江苏省社会科学基金项目“江苏省医疗器械产业创新生态系统建设研究”(17GLD023)
“双一流”学科创新团队建设项目“医药产业发展政策环境优化创新团队”(CPU2018GY39)
